
Greentech
Biotechnology
YOUR STEM CELLS CONNECT YOU TO LIFE
Biotechnology Revolution in Healthcare
www.greentechbio.com.tr

Greentech Biotechnology

Greentech Biotechnology, which has been offering specific, high quality and reliable products to the Turkish Pharmaceutical industry since the day it was founded in Turkey, continues to work with the belief of adding value to human health and social responsibility.

The main purpose of **Greentech Biotechnology**, which offers supportive, specific, and special products for many branches and diseases, is to increase the quality of people's life and support their treatment.

To achieve this goal, our products undergo a rigorous process, ensuring that they meet international standards for health products. This dedication is evident throughout all stages, from production to the end-user, as we prioritize delivering these products to our patients with a keen awareness of health and safety considerations.

Arthrex®

Contents

Arthrex IOSB®
(IntraOsseous Bioplasty)

Arthrex®

By performing decompression from a single entry point, the damaged area is reached and the necrotic tissue is cleaned with a flipcutter. Mesenchymal Stem Cells are obtained by aspirating bone marrow and adipose tissue from the iliac crest. Preferably, it is made into paste with bone marrow using cancellous bone or putty.







Frobell RB, Roos HP, Roos EM, Hellio Le Graverand MP, Buck R, Tamez-Pena J, Totterman S, Boegard T, Lohmander LS. The acutely ACL injured knee assessed by MRI: are large volume traumatic bone marrow lesions a sign of severe compression injury? Osteoarthritis and Cartilage 2008; 16:829-836

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Arthrex IOSB®
(IntraOsseous Bioplasty)

Instead of the necrotic tissue taken by Flip-Cutter, the tissue obtained from the spongy bone is brought to a paste-like consistency with Arthrex ACB® Bone marrow and Arthrex ACA® SVF and transferred from the same entry point to the damaged area. Optional cancellous (spongy) bone or putty can be used.









Farr J, Cohen SB. Expanding Applications of the Subchondroplasty Procedure for Treatment of Bone Marrow Lesions Observed on Magnetic Resonance Imaging. Oper Tech Sports Med 2013; 21:138-143

Arthrex Otogreft OATS®
Mozaik Plasty

The Disposable Arthrex Autograft OATS® set facilitates the retrieval of 6, 8, 10, or 12 mm osteochondral cartilage cylinders from a donor site above and lateral to the notch or above the sulcus terminal.

To accept the donor graft, a recipient socket is created in the chondral defect according to the appropriate depth.

The bone plug attaches with the collar pin distribution system for press-fit fixation. The fully disposable, size-specific system includes a recipient reamer, donor harvester, alignment bar, buffer, graft delivery tube, core extruder for controlled push-in core insertion, and optional graft driver.

The OATS 2.0 kit includes depth stop features to control the receiver area and transmitter plug in 8mm or 13mm lengths.

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Arthrex Innotere Paste CPC

The INNOTERE Paste-CPC is an impressive, injectable, self-hardening calcium phosphate cement, known for its user-friendly attributes.

The biomineral mixture is suspended in a non-aqueous carrier liquid. After placement in the implant area, this liquid is gradually replaced by body fluids, initiating a self-setting process. The resulting material predominantly consists of a mineral corresponding to the bone's mineral phase, addressing calcium deficiency.

Ready for use—no need for mixing. It does not settle in a syringe or delivery sheath, eliminating time constraints during application.

INNOTERE Paste-CPC, in addition to these optimized usability features, exhibits excellent mechanical and biological properties. It reaches approximately 12 MPa compressive strength after around 24 hours, approaching the compressive strength of cancellous bone. Maximum compressive strength, up to 45 MPa, is achieved within 2 - 4 days depending on the dimensions.



It undergoes a continuous rebuilding process.

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Arthrex Autocart®

For successful tissue formation, 3 main components are required; Scaffold, growth factors and regenerative cells.

These components form the “healing triad”. A scaffold is necessary to provide structure for tissue growth.

It guarantees mechanical integrity and provides a substrate (reaction) for cell growth. The growth factors are bioactive signaling molecules. They induce differentiation, proliferation, and metabolic activity, and determine the phenotype.

Cells also stimulate tissue regeneration in regenerative cells such as vital chondrocytes.

It describes the combined use of vital chondrocytes in the case of cartilage regeneration (Healing Triad).

Regenerative cells, platelet-rich plasma (growth factors), extracellular chondral fragments and autologous thrombin solution.

Shaver Blades
Harvesting chondrocytes and autologous cartilage tissue

GraftNet™
Autologous cartilage tissue collector

Arthrex ACP®
(Autologous Conditioned Plasma)
For the preparation of growth factors

Thrombinator™ System
For the preparation of autologous thrombin serum

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Arthrex GraftNet®

The GraftNet device is used to obtain the resected tissue by attaching it to the aspirator outlet of the arthroscopic shaver.

This autologous and resected tissue augmentation can be used to fill therapeutic and surgical fields. It is aimed to form cartilage when obtained with a GrafNet device and resection with a 5.0 mm bone cutter.

GraftNet™ Autologous Tissue Collector
Vacuum-activated GraftNet device for a multitude of applications designed to collect autologous tissue. When connected to an arthroscopic shaver, the GraftNet device is used to remove tissue debris from a surgical site. This recovered autologous tissue is collected in an easily accessible, sterile filtered chamber. The GraftNet autologous tissue collector makes accessing autograft tissue as simple as Cut & Collect.

- Universal adapters allow for easy mounting
- Collects autologous bone or cartilage particles
- Quick access to recovered tissue volume
- Shaver controls the particle size when using the device

Indicators: ACL: BTB harvest side filling
When preparing an ACL tunnel, GraftNet is used to recover bone that can be used to fill the harvest side.

Osteotomy: Osteophyte collection to fill the osteotomy space. Intra-articular osteophytes are present in the majority of patients who require HTO. Using the GraftNet device, these osteophytes can be easily harvested and used to fill the osteotomy cavity.

Cartilage: A particulate, cellular articular cartilage material can be used to support a focal articular cartilage defect after a microfracture.

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Usage:
Plug GraftNet into a shaver or vacuum device. Following autologous tissue collection, disconnect the GraftNet tissue harvester from the aspiration and tissue resection device. Next, detach the enclosure of the GraftNet device to access the collection filter. Pull the plunger back from the GraftNet device to access the collected autologous graft. The harvested tissue is then concentrated with autologous fluid such as ACP (Platelet-rich Growth Factor) Arthrex ACB® (bone marrow-derived stem cell) or Arthrex ACA® (Adipose tissue-derived stem cell) before being delivered to a surgical site.

Optional:
For better use, the autologous bone graft can be mixed with Arthrex ACP-ACB-ACA alone or in combination with autologous thrombin with the Thrombinator device.

Arthrex Trombinator®

Cartilage tissue collected with GraftNet is mixed with Arthrex ACP® or Arthrex ACB® Bonemarrow in a thrombinator to form a paste and transferred to the damaged tissue.

The viability of the resected cartilage tissue was on average 93% (+/-18%) of the viability of the shaved cartilage tissue.

No significant difference was observed between the viability of resected cartilage tissue tested at different times or obtained with different modes.

On day 7, metabolic activity was 80% (+/-30%) of the level on day zero. When the two cutting modes were compared, there was no significant difference in metabolic activity rates.





The GrafNet Device can be used attached to an Atroscopic Shaver, such as a 5.0 mm bone cutter, to obtain cartilage tissue.

The viability and activity in the resected tissue continues for at least 7 days.

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Arthrex Meniscal Viper®

The Arthrex Meniscal Viper® Suture Set offers suture capability to repair the posterior horn meniscus with a convenient and effective pass method.

The disposable suture is completely Amorphous PLDLA copolymer and is safely absorbed within 36 weeks.

It shows safe and effective performance with its versatile clinical studies with two-year follow-up.

Arthrex Meniscal Viper® enters the joint space and reduces fat pad interference. The low profile, anatomically curved shaft of the Viper consists of cavities that facilitate tight coupling insertion.

Disposable Arthrex Meniscal Viper® Suture & Small Knot Pusher Meniscus Dart Bar and Meniscus Dart Cover are suitable for Arthroscopic All Inner Meniscus Repair.





It reduces tearing in the joint.

It offers an easy-to-use option to the surgeon performing the procedure. To pass the needle through the tear, the thumb loop is deployed forward until the positive stop is opposed.

The all-inside vertical FiberWire suture placement option and Meniscal Dart provides the most stable and safest arthroscopic and full-inside meniscus repair solution.

Arthrex Meniscal Viper® is used to protect against tearing and provides additional stability in hard-to-reach meniscal areas.

The Arthrex Meniscal Viper® Device is suitable for suture reloading (2-0 FiberWire suture). Arthrex Meniscal Viper® increases efficiency and reduces costs.

Arthrex Angel cPRP System®

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Introduction

The Angel system utilizes a proprietary platelet sensor and 1-button automation to prepare customized platelet-rich plasma (PRP) formulations. It is the only PRP device that can deliver platelet concentrations up to 18 × baseline, with adjustable leukocyte concentrations.

Features and Benefits

- Proprietary platelet sensor system
- Adjustable platelet concentrations
- Adjustable white blood cell (WBC) concentrations
- Flexible processing volume 40 – 180 ml
- Each processing kit can process 3 cycles up to 180 ml on the same patient
- Programmable – can store up to 30 custom processing protocols
- Closed system, delivers PRP, PPP, and red blood cells (RBCs) into separate, sterile compartments

Mechanism of Action

Outside the bloodstream, platelets become activated and release proliferative and morphogenic proteins. These proteins appear to work synergistically to invoke the following benefits:[1 - 3]

- Induce proliferation and differentiation of various cell types (eg, progenitor cells, osteoblasts, epidermal cells)
- Enhance / modulate production of collagen, proteoglycan and Tissue Inhibitor Metalloproteinases (TIMP)
- Stimulate angiogenesis and chemotaxis

Angel® System PRP Output



In order to evaluate the difference between the Angel system PRP output and whole blood, the Angel system PRP was prepared from the venous blood of 6 healthy donors at hematocrit settings of 2 %, 5 %, 7 %, 10 %, and 15 %. The concentration of platelets, white blood cells (WBC), and neutrophils (NE) were measured with a standard complete blood count (CBC).

Angel® System Bone Marrow Concentration

Indication-Specific PRP Preparations From Bone Marrow Aspirate

Introduction

Technology is what sets the Angel system apart from the competition. The Angel cPRP and bone marrow processing system utilizes a proprietary platelet sensor and 1-button automation to prepare customized PRP concentrate from bone marrow aspirate (BMA). Bone marrow is a rich source of platelets, nucleated cells, and progenitor cells.

The Angel device is the only one to provide PRP concentrate from BMA with adjustable cellular levels.

Features and Benefits

- Proprietary platelet sensor system
- Adjustable platelet concentrations
- Adjustable white blood cell (WBC) concentrations
- Flexible processing volume 40 - 180 ml
- Each processing kit can process 3 cycles up to 180 ml on the same patient
- Programmable – can store up to 30 custom processing protocols
- Closed system delivers PRP, PPP, and red blood cells (RBCs) into separate, sterile compartments

Mechanism of Action

Bone marrow-stimulating techniques, such as abrasion and microfracturing, have been advocated for over 20 years. Bone marrow is a source of stem cells and progenitor cells that:

- Differentiate into a variety of tissues (bone, cartilage, tendon, ligament, fat, muscle, nerve)
- Have a role in the maintenance and repair of several other tissues.

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Preparation



Loading



Centrifugation



Fully automated separation

Arthrex ACP®
(Autologous Conditioned Plasma)

Arthrex

GREENTECH BIOTECHNOLOGY

Arthrex ACP®, the most effective way to obtain platelet-rich Growth Factor Deposit;

- 10 years of continuous publication and clinical work
- Easy to Use-High Number of Growth Factors
- Compact design that can be used even in office environment
- Minimum contamination-Maximum Protection
- Adjustable Concentration levels
- Short preparation time of 5 minutes
- FDA Approved - FIDIKA Approved
- CE Certified - Medical Device Institution Registration - UTS Certified
- Officially registered h Official and proven cell counts
- Most preferred product in the world

ARTHREX ACP®
AUTOLOGOUS
CONDITIONED PLASMA

FDA
FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Arthrex ACP®
(Autologous Conditioned Plasma)

Early knee osteoarthritis treatment Arthrex ACP® has been clinically proven to be a one-year success according to the results of the efficacy study, and 78% success is achieved with ACP when the Womac results are compared.

Clinical trial approved by FDA.

Intra-Articular Autologous Conditional Plasma Injections Provide Safe and Effective Treatment for Osteoarthritis of the Knee

Knee osteoarthritis (OA) is a leading adult joint disease. The severity of knee OA is commonly classified using the Kellgren-Lawrence (K-L) grading system. This rating ranges from 0 to 4, with 4 representing severe OA. About 10% of men over the age of 60 and 13% of women experience knee Osteoarthritis. Intra-articular IA injection of platelet-rich plasma (PRP) is an emerging treatment option for knee osteoarthritis. PRP is an attractive method because it uses the patient's own blood. Depending on the preparation method, PRP can be leukocyte-poor (Leukocyte-poor -LP-PRP) or leukocyte-rich (Leukocyte-rich LR-PRP). Studies have shown promising results in knee Osteoarthritis patients treated with LP-PRP.

Intra-articular autologous conditioned plasma injections provide safe and efficacious treatment for knee osteoarthritis. AmJ Sports Med. 2016;44(4):884-891. doi:10.1177/0363546515624678.



Results

· No side effects have been reported due to ACP application.
· The ACP group showed a significant decrease in WOMAC scores 1 week after administration. These scores continued to decrease until after 3 months.
· A plateau was observed up to 12 months.
· There was a statistically significant difference between the WOMAC scores of the ACP group and those of the placebo group starting from week 2.
· WOMAC scores for the placebo control group increased by only 7% from baseline, while scores in the ACP group increased by 78%.
· The study concluded that ACP was safe to use and that the ACP group had better pain relief and functional recovery in knee osteoarthritis.



Arthrex ACP Max™



The ACP Max system allows for the efficient concentration of platelets from whole blood volumes of 30 mL, 60 mL, or 90 mL. The system's final output results in a neutrophil-poor PRP solution with up to 12× platelet concentration over baseline.[1-3]

Features and Benefits

- Always closed system to collect and prepare PRP with swabable valves for sterile liquid transfer to injection syringe
- Large-volume collection syringe allows the preparation of ACP Max, a PRP with unique cellular composition
- Building on the success of the double-syringe design, this system is compatible with existing ACP preparation material*

Key Points

- Up to 90 mL processing volume
- Compatible with ACP centrifuges and rotors
- Preparation of hyperconcentrated ACP
- Preparation of large ACP volumes

Arthrex ACP Max™





Features and Benefits

- Reliable double-syringe technology
- Processing capabilities for volumes of 30 mL 60 mL, and 90 mL
- System is compatible with current Drucker and Hettich centrifuges
- The system effectively concentrates platelets up to 12× over baseline while reducing neutrophil concentration by up to 98.9%
- concentration by up to 98.9%1-3

References

1. Arthrex, Inc. Data on file (APT 5368). Naples, FL; 2021.
2. Arthrex, Inc. Data on file (APT 5535). Naples, FL; 2022.
3. Arthrex, Inc. Data on file (APT-5756). Naples, FL; 2022.



ACP Max™ PRP - Cellular Composition







References

1. Andia I et al: Basic Science: Molecular and Biological Aspects of Platelet-Rich Plasma Therapies. Operative Techniques in Orthopaedics. 2012; 22(1): 3 - 9

* The ACP Max system is compatible with Hettich Rotofix 32A and the Drucker Horizon 24-FLEX centrifuges. Purchase of compatible centrifugation buckets may be necessary.

The ACP Max system produces an average of 5 mL PRP, containing approximately 3×, 7×, and 12× platelet concentrations over baseline for 30 mL, 60 mL, and 90 mL processing volumes of WB, respectively. This concludes that PRP produced from the ACP Max system is depleted of red blood cells and neutrophils, resulting in a 95% to 99% reduction in red blood cells and a 97% to 99% reduction of neutrophiles, depending on processing volume. Overall, the ACP Max system can produce PRP with up to 12× concentration of platelets over baseline, while depleting inflammatory cells.

Arthrex ACP® Tendo

Growth Factor-Biyoactive Collagen

Arthrex®

GREENTECH BIOTECHNOLOGY

Türkiye'de İLK VE TEK

10 Years ACP

Growth factors obtained by peripheral and conditioned plasma method maximize the treatment by providing a high repair process. Bioactive Collagens provide the formation of Chondrocyte and Fibroblast cells after interacting with Growth Factors.

FDA

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

Arthrex ACB® BMAC

Mesenchymal Stem Cell Viability (viability rate) obtained with (Autologous Conditioned Bone Marrow) is 99.00
Number of viable cells in 1 microliter is 490.4



ÖZEL
DEREN LABORATUVARI
TIBBİ LABORATUVAR TETKİK SONUÇ RAPORU
Laboratuvar Ruhsat No : 80/ Y-2

Ad Soyad	: GREENTECH BIYOTEKNOLOJI A.S.	Analizi İsteyen	: ÖZEL-BUT
T.C. Kimlik No	: 41*******	Numune Kayıt Zamanı	: 04.05.2021 15:06:55
Doğum Tarihi	: 01.01.1969	Numune Alma /Kabul Zamanı ve Yeri	: 04.05.2021 15:07:56 ÖZEL-BUT
Cinsiyet	: Bilinmeyen	Uzman Onay Zamanı	: 04.05.2021 12:36:43
Örnek No	: 2114167	Rapor Verme Zamanı	: 04.05.2021 16:07:34
Dosya No	:	Revizyon Numarası	: 00
Rapor No	: 534587.2114167.2021		

UYGULANAN TESTLER	SONUÇ	BİRİM	REFERANS ARALIĞI	ÖNCEKİ SONUÇLAR	NUMUNE TÜRÜ
Akım Sitometri					
CD14 oranı (Kemik İliği)	75.3 (Total popülasyonda %4.0)	%			Kemik İliği
CD34 oranı (Kemik İliği)	CD34 % 1.3 490.4 CELLS/MİKROLİTRE	%			Kemik İliği
CD45 oranı (Kemik İliği)	88.0	%			Kemik İliği
Canlı hücre oranı (7AAD) (Kemik İliği)	99.0 CANLILIK ORANI HÜCRE 1.0 ÖLÜ HÜCRE SAYISI	%			Kemik İliği

Lenfosit:%22,0
Monosit:%4,0
Granülosit:%70,0
WBC:32,7
NUMUNE TÜRÜ:KEMİK İLİĞİ-04.05.2021

SAYGILARIMIZLA,
Ersin GÖNÜLTAŞ
Biyokimya ve Klinik Biyokimya Uzmanı
Dip. No: 2588

Önemli Uyarı
Sonucun hastanın öyküsü, klinik ve diğer laboratuvar bulguları ile uyumsuz olduğunu düşündüğünüz ve etkisizleti laboratuvar sonucu ile girişimsel işlem yapılacağı durumlarda sonucun doğrulanması için laboratuvarla temasa geçmemiz rica olunur.
- Bu sonuçlar sadece incelenmesi yapılan numuneler ile ilgilidir.
- Bu rapor, laboratuvarımız yazılı izni olmadan kısmen kopyalanıp çoğaltılamaz,imzasız ve kaşesiz raporlar geçersizdir.
Revizyon Açıklama :
(Akredite analizler * ile işaretlenmiştir.)
* BAŞKURU LABORATUVARINDA ÇALIŞILMIŞTIR
Cevizlidere Mh.Mevlana Blv.No:221/1907(Edvenkule) Çankaya-Ankara-Tel:+90 312 466 33 55-438 43 03(3 Hat)Fax:+90 312 438 43 58-www.derenlab.com/info@derenlab.com

FRM-030-Rev: 02/03.01 LABORATUVARIMIZI TERCİH ETTİĞİNİZ İÇİN TEŞEKKÜR EDER SAĞLIKLI GÜNLER DİLERİZ Sayfa No: 1 / 1

Arthrex ACA® SVF

Mesenchymal Stem Cell Viability (viability rate) obtained with (Autologous Conditioned Adipose) is 99.4
Number of viable cells in 1 microliter is 560.80

ÖZEL
DEREN LABORATUVARI
TIBBİ LABORATUVAR TETKİK SONUÇ RAPORU
Laboratuvar Ruhsat No : 80/ Y-2

Ad Soyad	: GREENTECH BIYOTEKNOLOJI A.S.	Analizi İsteyen	: ÖZEL-BUT
T.C. Kimlik No	: 41*******	Numune Kayıt Zamanı	: 05.04.2022 17:25:11
Doğum Tarihi	: 01.01.1969	Numune Alma /Kabul Zamanı ve Yeri	: 05.04.2022 17:41:57 ÖZEL-BUT
Cinsiyet	: Erkek	Uzman Onay Zamanı	: 06.04.2022 15:05:17
Örnek No	: 2339938	Rapor Verme Zamanı	: 0
Dosya No	:	Revizyon Numarası	: 00
Rapor No	: 534611.2339938.2022		

UYGULANAN TESTLER	SONUÇ	BİRİM	REFERANS ARALIĞI	ÖNCEKİ SONUÇLAR	NUMUNE TÜRÜ
Akım Sitometri					
CD14 oranı (Kanın Yağı)	%78.3 (Total Polasyonda %4.2)	%			Kanın Yağı
CD34 oranı (Kanın Yağı)	CD 34 % 1.3 560.80 cells/mikrolitre	%			Kanın Yağı
CD45 oranı (Kanın Yağı)	89	%			Kanın Yağı
Canlı hücre oranı (7AAD) (Kanın Yağı)	99.4 Viyabilite				

NUMUNE TÜRÜ:ADİPOZ DOKU -05-04-2022 WBC:6000

Uzm.Dr. Tevfik HONCA
Biyokimya ve Klinik Biyokimya Uzmanı
Dip. Tes.No: 118187

Önemli Uyarı
Sonucun hastanın öyküsü, klinik ve diğer laboratuvar bulguları ile uyumsuz olduğunu düşündüğünüz ve etkisizleti laboratuvar sonucu ile girişimsel işlem yapılacağı durumlarda sonucun doğrulanması için laboratuvarla temasa geçmemiz rica olunur.
- Bu sonuçlar sadece incelenmesi yapılan numuneler ile ilgilidir.
- Bu rapor, laboratuvarımız yazılı izni olmadan kısmen kopyalanıp çoğaltılamaz,imzasız ve kaşesiz raporlar geçersizdir.
Revizyon Açıklama :
(Akredite analizler * ile işaretlenmiştir.)
* BAŞKURU LABORATUVARINDA ÇALIŞILMIŞTIR
Cevizlidere Mh.Mevlana Blv.No:221/1907(Edvenkule) Çankaya-Ankara-Tel:+90 312 466 33 55-438 43 03(3 Hat)Fax:+90 312 438 43 58-www.derenlab.com/info@derenlab.com

FRM-030-Rev: 02/03.01 LABORATUVARIMIZI TERCİH ETTİĞİNİZ İÇİN TEŞEKKÜR EDER SAĞLIKLI GÜNLER DİLERİZ Sayfa No: 1 / 1

BIOLOGICAL THERAPEUTIC SOLUTIONS

FDA Onaylı Uluslararası Standart

FDA Approved, International efficacy, safety and reliability have been clinically proven.

Arthrex ACA® SVF

Introduction

Stem cells from adipose tissue (AdSC), which are located in the stromal vascular fraction (SVF), share similar properties with bone-marrow-derived stem cells. They can differentiate into different cell lines such as bone, fat, cartilage, and muscle and secrete a large number of cytokines and growth factors,1 - 4 but in comparison to bone-marrow-derived stem cells, they are easier to collect for clinical application and show higher isolation yields.

Composition of SVF

In addition to their multipotent differentiation potential, adipose-derived stem cells also secrete a large number of cytokines and growth factors, such as hepatocyte growth factor (HGF), interleukin-6 (IL-6), or transforming growth factor beta 1 (TGF-β1), that support tissue regeneration.2, 3, 4, 19 The SVF also comprises some endothelial cells, smooth muscle cells, erythrocytes, leukocytes, adipocytes, and the extracellular matrix, which can act as a temporary scaffold that also contains matrix remodeling enzymes.

FDA Onaylı Uluslararası Standart

FDA Approved, International efficacy, safety and reliability have been clinically proven.

Features and Benefits

- SVF technique offers an easy and fast solution for harvesting and processing nonhomogenous liquids such as adipose tissue
- No enzymes – mechanical processing whereby the SVF can be collected as a pellet6
- Proven synergistic effect – PRP promotes cell proliferation and differentiation of AdSC
- Supports tissue regeneration

Major Effects of SVF

- Reduction of local inflammation
- Prevention of tissue fibrosis
- Anti-apoptotic
- Supports angiogenesis and tissue remodeling
- Enhancement of endogenous stem cell recruitment and proliferation
- Reduction of osteophyte formation and synovial inflammation
- Reduction of cartilage degradation.

Production of Arthrex ACA® SVF

Mechanism of Action



Preparation



Fat tissue harvesting from an appropriate donor site (eg, belly, waist, or thigh)



Isolation of fat graft

Processing



Isolation of SVF

SVF final product state

FDA Onaylı Uluslararası Standart

FDA Approved, International effectiveness, safety and reliability have been clinically proven.

CD Markers for Different Cell Types

Arthrex®

Cell Type	Positive Markers	Negative Markers
Pericytes	CD140b (PDGFRβ), CD146, NG2	CD31, CD34, CD144, vWF
Endothelial and Progenitor Cells	CD31, CD34, CD90, CD146, vWF	CD45, CD140b, CD144
Adipose-Derived Stem Cells	CD13, CD29, CD34 (variable), CD44, CD90, CD104a	CD14, CD31, CD45, CD106, CD144, CD146, αSMA

Definition and Importance of CD Markers

CD Markers:
Cluster of Differentiation (CD) markers are cell surface molecules used to identify and characterize specific cell types. These markers are typically proteins or glycoproteins that can be detected using antibodies.

Importance and Role:
CD markers play a crucial role in the field of immunology and cell biology. They are essential for identifying and isolating different cell populations, understanding immune responses, and studying cell development.

In the scheme above, we've highlighted key CD markers associated with pericytes, endothelial and progenitor cells, and adipose-derived stem cells. For instance, the presence of CD34 and CD31 on endothelial and progenitor cells is often indicative of vascular and angiogenic processes.

Understanding CD markers is crucial for accurately identifying and studying cell populations, aiding in the development of targeted therapies and diagnostic tools.

Pericytes:
CD140b (PDGFRβ): Essential for pericyte function, involved in regulation of vascular development and stability.
CD146: Facilitates pericyte interactions with endothelial cells, contributing to vascular integrity.
NG2: Marks pericytes and plays a role in cell-matrix interactions within blood vessels.

Endothelial and Progenitor Cells:
CD31: Mediates endothelial cell adhesion and is a key marker for endothelial lineage.
CD34: Involved in endothelial progenitor cell migration and angiogenesis.
CD90: Supports endothelial cell survival and angiogenic potential.
CD146: Associated with endothelial cells and contributes to vascular development.
vWF: A critical component in blood clotting, indicating endothelial activation.

Adipose-Derived Stem Cells:
CD13: Regulates cell adhesion and migration, contributing to stem cell function.
CD29: Integrin involved in cell adhesion and interaction with extracellular matrix.
CD34 (variable): Marks a subset of adipose-derived stem cells with regenerative potential.
CD44: Cell surface receptor involved in cell-cell interactions and signaling.
CD90: Supports stem cell differentiation and tissue repair.
CD104a: Involved in cell adhesion and migration, contributing to tissue regeneration.
CD14, CD31, CD45, CD106, CD144, CD146, αSMA: Negative markers indicating the absence of specific cell types or characteristics.

MediGraft™

THE DEVICE IS COMPOSED BY AN INTERNAL METAL GRID WITH ABOUT 100 HOLES WITH MICROBLADES DESIGNED TO CUT DIFFERENT TYPE OF TISSUES.

Medigraft™ is a disposable procedural kit designed for the mechanical processing and disaggregation of a biological tissue sampling to be used in the field of regenerative medicine and surgery. Thanks to a micro rotating system with the motion of the helix and counter helix present on the internal grid of the device, the sample is gently dissociated into regenerative tissue units, obtaining a highly viable cell product suitable for infiltration into the injured tissue.

Micro units of cell clusters obtained thanks to a gentle mechanical disaggregation with Medigraft devices, can guarantee a final product "without the use of enzymes" with high vitality, great regenerative capacity in suspension of physiological, PRP or hyaluronic acid, which can be used for injective treatments or in combination with a scaffold.

The micro units of cell clusters are rich in mesenchymal progenitor cells and EPCs, with a large presence of fibroblasts, pericytes and growth factors present in the vascular-stromal niche of the processed tissue. (Zanzottera et al.,2014)



The small size of the clusters (50-70 microns) allows a high rate of cellular vitality.

MediGraft™

Medigraft™ is a disposable and sterile procedural kit containing all the instruments to perform an innovative surgical procedure to obtain regenerative Cell Micro Clusters.

The Medigraft™ technology does not use enzymes to break up the tissue, but thanks to a gentle mechanical action, the collected tissue is disaggregated into Cellular Micro Clusters with high regenerative capacity.

All the components of the kit are included in a rigid tray with a sterile cloth 60x90 mm that can be used to prepare the surgical field.

In the kit it's also included a 4mm biopsy punch, or a scalpel, which allows to pick up the samples size suitable for the procedure.

The surgical tweezers can be used to put the sample inside the device.

The sampling site can be medicated with special Steril-Strips present in the kit.

The samples are processed with the Medigraft device thanks to the dedicated line of machines.

MEDIMAX MG

The Medimax MG system is a sample preparation system for the automated, mechanical disaggregation of human tissues. The Medimax MG system makes tissue preparation safe and independent of operator technique, and facilitates standardizing the preparation of all tissue types..

The Medimax MG system can be used with the following products:

MEDIGRAFT A ▪ MEDIGRAFT B ▪ MEDIGRAFT MAX

The compact Medimax MG unit is the heart of the system. It works with all types of Medigraft and operates at a constant speed of approximately 80 rpm.

MediGraft™



Mesenchymal cells (MSCs) are characterized by their ability to differentiate into different types of specialized cells, but it is their trophic, paracrine and immunomodulatory functions that have the greatest therapeutic impact in regenerative medicine. The traditional view, focused on the differentiation of these cells, must therefore be broadened to include their role as cellular modulators, capable of secreting cytokines and bioactive signals in response to the microenvironment.

The primary trophic property of MSCs is to secrete growth factors and chemokines that induce cell proliferation, stimulate resident cells and promote angiogenesis through paracrine effect.**(Mancuso et al.,2019) (de Girolamo et al.,2016).**

Their anti-inflammatory and immunomodulatory capacity is also essential in restoring the natural nvironment and promoting healing and regeneration of the injured tissue.

MSCs have been isolated and characterized in a variety of adult tissues including bone, adipose tissue, dermis, synovial fluid, periosteum, cord blood, placenta, and amniotic fluid.

The frequency of MSCs and the native concentration in different adult human tissues was studied as reported in the table below:

Human tissue source	Native CFU-F concentration range per ML of fluid/liquid	MSCs frequency range (CFU-F/106 nucleated cells)
Bone marrow aspirate	09-664	10-83
Peripheal blood	0	0-2
Adipose/lipoaspirate	2.058-9.650	205-51.000
Synovial fluid	4-14	2-250
Dermis	Nd	74.000-157.000
Amniotic fluid	3	9.2

Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine
Matthew B Murphy, Kathryn Moncivais and Arnold I Caplan

The presence of MSCs throughout the body is also evident in light of recent scientific works according to which most MSCs are of perivascular origin and that there is a direct correlation between the frequency of MSCs and the amount of blood vessels present in the stromal tissue.It is known that pericytes are the source of MSCs, which extravasate from the endothelial lumens of blood vessels to monitor and respond to signals in all vascularized tissues of the body.

(Crisan et al.2008). Once the microenvironment is restored, MSCs return to their native state of pericytes anchored to blood vessels. **(Murphy et al. 2013)**

The availability and versatility of these extraordinary cells make them an excellent treatment option for a wide variety of clinical conditions.

ALLOGENEIC EXOSOME

Innovative Isolation / Filtration Technology – ExoSCRT

- ExoSCRT technology is apt for isolating quality exosomes with excellent efficacy and GMP mass production, compared to other existing exosome isolation technologies.
- ExoSCRT Exosomes maintain the regenerative, immunomodulatory and anti-inflammatory effects to replace stem cells.
- Through continuous R&D, ExoSCRT has increased productivity and improved quality, while reducing time and cost.





ALLOGENEIC EXOSOME - PROFILING OF COMPONENTS

Allogeneic Exosome's **Protein and Growth Factors**

ExoCoBio's ExoSCRT® Exosome contains 1,008 growth factors and proteins.

- Protein analysis using LC-MS/MS confirms that ExoSCRT Exosome contains a total of 1,008 proteins
- Contains 200 proteins for Skin rejuvenation



1) Front Immunol. 2018, 25;9:1377
2) Non-coding RNA Investig. 2018, 2:28
3) Physiol Genomics. 2011, 43:543–556
4) ExoCoBio 자체 분석 (prediction) 결과

AUTOLOGOUS EXOSOMES

AUTOLOGOUS PLATELET EXOSOMES

AutologIX, is an innovative therapy that utilizes your own body's natural healing properties to promote regeneration and tissue repair. This cutting-edge treatment involves isolating exosomes, tiny membrane-bound vesicles, from your own platelets and delivering them directly to the area in need of treatment

AUTOLOGIX

BIOLOGICAL INNOVATIONS

AUTOLOGIX

Autologix's exosomes contain a powerful mix of growth factors and signalling molecules that can stimulate healing, reduce inflammation, and promote tissue regeneration. Autologix represents a personalized approach to regenerative medicine that harnesses the body's own healing potential to accelerate recovery and restore function. If you're looking for a safe, effective, and minimally invasive alternative to traditional treatments, AutologIX's autologous platelet exosome therapy may be the solution you've been searching for.

PROTSmart 6 is the result of a combination between the filtration technology based on capillary membranes and the concentration of blood derived plasma. ProtSmartis designed to collect and hyper-concentrate autologous exosomes from peripheral blood to be used in the field of regenerative medicine. It isa medical device Class IIa,a selective concentrator of exosome through an innovative technology of ultrafiltration .The filtration cut-off is close to ⊥15.000 KDa with average perfusion diameter< 5nm.Due to its selective ability to concentrate and ultrafilter, water and fragments of salt ions are pushed out in the bag while exosomes, proteins and cells are collected internally into the tubes.During centrifugation of IDRIA G exosomes are released and remain suspended in the plasma. The physicians process 2x IDRIA G 28ml tube which would give 27-28ml of Plasma in a single 8-minute spin(1500 rgf).

Accelerated healing	Reduced inflammation	Reduced inflammation	Pain relief	Minimally invasive

AUTOLOGOUS EXOSOMES
AUTOLOGIX INDICATIONS

Musculoskeletal injuries
Autologous platelet exosomes therapy may be beneficial for treating musculoskeletal injuries, such as tendonitis, ligament injuries, and muscle strains. The therapy can stimulate tissue repair and regeneration, reducing inflammation and promoting healing.

Skin rejuvenation
Autologous platelet exosomes therapy may promote skin rejuvenation by stimulating the production of collagen and elastin, reducing the appearance of fine lines and wrinkles, and improving skin texture and tone.

Hair loss
Autologous platelet exosomes therapy may be beneficial for promoting hair growth and improving hair quality. The therapy can stimulate hair follicle stem cells, promoting hair growth and thickening.

Pain management
Autologous platelet exosomes therapy may help alleviate pain associated with various conditions, such as osteoarthritis, tendinopathy, and sports injuries. The therapy can reduce inflammation and promote tissue repair, which can help relieve pain.

Dermatological conditions
Autologous platelet exosomes therapy may be beneficial for treating various dermatological conditions, such as acne, psoriasis, and eczema. The therapy can reduce inflammation and promote tissue regeneration, improving skin health and function.

Wound healing
Autologous platelet exosomes therapy may accelerate the wound healing process by promoting tissue regeneration and reducing inflammation. The therapy can stimulate the growth of new blood vessels, improving oxygen and nutrient delivery to the wound site.

Arthrex Hyalur®
Biologic Hyaluronic Acid



Arthrex Hyalur® is manufactured in accordance with FDA and Pharmacopeia Standards

The viscoelasticity of synovial fluid is significantly affected in patients with degenerative joint disease (osteoarthritis). This leads to mechanical stress on the joint and disruption of the articular cartilage, resulting in limited joint mobility and pain. Thanks to its high molecular weight (2,4 MilDa), Arthrex Hyalur® contributes to the reduction of pain with its lubricating and shock-absorbing properties, provides high performance and improved joint mobility.

This effect can last from 6 months to 12 months after the treatment cycle.

"Arthrex Hyalur® is a biological viscoelastic joint fluid that promotes its restoration.

Biological Revolution in Osteoarthritis Treatment

In patients with degenerative joint disease (osteoarthritis), the viscoelasticity of the synovial fluid is significantly affected. This leads to mechanical stress on the joint, resulting in deterioration of the articular cartilage, limited joint mobility and pain.

Thanks to the shock absorbing properties of hyalur, it provides pain reduction and improved joint mobility.





Features & Benefits of Biological high quality hyaluronic acid

Original Product Warranty - Sealed hard-lid blister - Easy to use - Fixed piston with solid tip - Injection safety - Constant injection force during use

- 2% (20 mg biyologic sodium hyaluronate/ml)
- 2.400 kDa, Non-Crosslinked
- 2 ml volume Not of animal origin

Therapeutic Effect

Inflammatory processes – Anti-Inflammation:
It inhibits interleukin-1β expression and associated synthesis of metalloproteinases and reactive oxygen species.

Cartilage degradation - Chondro protection:
It increases chondrocyte proliferation and proteoglycan and glycosaminoglycan synthesis, while reducing chondrocyte apoptosis.

Risky Synovial Fluid – Synovial Fluid Recovery:
Promotes increased internal production of Hyaluronic Acid, reduces friction and protects with shock absorption effects.

Arthrex Hyalur®
Biologic Hyaluronic Acid





Biological high quality hyaluronic acid

· Original Product Warranty - Sealed hard-lid blister

· Easy to use – Fixed piston with solid tip

· Injection safety – Constant injection force during use

· Hyalur is used for injection into the knee joints to restore the natural viscoelastic properties (viscous reinforcement) of synovial fluid in humans.

Hyalur is indicated for the treatment of pain and restricted movement as a result of degenerative or traumatic changes in the knee joint area.

Hyalur is a high quality hyaluronic acid.

It is produced in accordance with European standards based on the standards in the European Pharmacopoeia.

- 2% (20 mg biyologic sodium hyaluronate/ml)
- 2.400 kDa, Non-Crosslinked
- 2 ml volume
- Not of animal origin



1. Maheu et al, Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol. 2011; 29(3):527-35 (Data were collected using a hyaluronic acid comparable to Hyalur.)

2. Reviewed in Altman et al. BMC Musculoskeletal Disorders (2015) 16:321. (Data were collected using a hyaluronic acid comparable to Hyalur.)

ORTHOFLEX ONE®

ORTHOFLEX one

We cannot ignore pain!
Why hurt when you can prevent it?

orto brand ∞
enjoy your life

Product:	ORTHOFLEX One®
Composition:	Hyaluronic Acid+ Chondroitin Sulfate
Indication:	Osteoarthritis
Concentration:	60 mg/3 ml (2%) hyaluronic acid 90 mg/3 ml (3%) chondroitin sulfate
Treatment:	1 injection/treatment OA level 3 and 4
Molecular weight:	3 MDa
Effect:	cartilage repair, mobility improvement, pain relief
Packaging:	3 ml prefilled syringe in medical blister
Sterilization:	autoclave
Shelf life:	2 year
Storage:	between +2°C and +25°c

ORTHOFLEX One® is the first and alone commercial viscose supplement combining HA (hyaluronic acid) and CS (chondroitin sulfate) in the treatment of degenerative joint disease.

ORTHOFLEX One® is a sterile, viscoelastic solution, containing two highly purified crosslinked biological polymers: hyaluronic acid in concentration of 60 mg per 3 ml and chondroitin sulfate 90 mg per 3 ml.

The solution has high molecular weight - 3,0 MilDa - which guarantees its excellent efficiency and a strong therapeutic effect.

ORTHOFLEX One® presents itself in a prefilled, sterile, single dose syringe, that will be injected as 1 dose per treatment.

1 injection per treatment
For articular cartilage repair
intra-articular injection
The unique combination of **CROSS-LINKED HYALURONIC ACID + CHONDROITIN SULFATE**

How does it work?
Hyaluronic acid is a major component of the synovial fluid and cartilage and is responsible for the lubrication and cushioning in joints. It decreases friction between joint surfaces and protects soft tissue from trauma, by acting as a shock absorber.

Hyaluronic acid also has analgesic, anti- inflammatory and antioxidant effects, stimulates proteoglycan synthesis and facilitates the evacuation of cartilaginous remains.

ORTHOFLEX ONE®

ORTHOFLEX one



The outstanding viscoelastic performance ORTHOFLEX one® is due to the unique crosslinking process.

What are the indications of ORTHOFLEX One®?

ORTHOFLEX One® is a product for viscose supplementation, which is a safe, efficient and well established treatment in osteoarthritis, consisting of injecting a hyaluronic acid and chondroitin sulfate based solution into the affeted synovial joint.

ORTHOFLEX One® acts as a temporary replacement and supplement for synovial fluid. It is also recommended for :
·Post–arthroscopy pain relief,
·Following meniscus repair procedure,
·Following previous crossed ligament reconstruction
·As auxiliary treatment for patients with osteochondral defects.

1 injection per treatment
For articular cartilage repair
intra-articular injection
The unique combination of **CROSS-LINKED HYALURONIC ACID + CHONDROITIN SULFATE**

The supplement of chondroitin sulfate not only provides pain relief, mobility improvement and cartilage protection, but also cartilage regeneration.

This cartilage repair is particularly beneficial in severe Osteoarthritis (Grade 3-4).

The use of Chondroitin Sulfate as a crosslinking agent increases the biocompatibility and biodegradability of the natural polymer, creates the necessary conditions to delay cartilage degeneration and promotes regeneration.

What is the treatment with **ORTHOFLEX One®?**
Just one injection per treatment can treat the symptoms of osteoarthritis.

ORTHOFLEX One® is administered in the affected joint as a single dose per treatment.

If the treatment is bilateral, a separate syringe should be used for each knee.

Approved for all synovial joints (particularly the knee and hip, but also the ankle, shoulder, elbow, wrist, fingers, toes, the temporo mandibular and facet joints).

This effect can be maintained for up 1 year. In order to prevent complications, the treatment should be repeated. Any joint effusion present should be removed by joint aspiration, before injecting **ORTHOFLEX one®**.

ORTHOFLEX FORTE®

ORTHOFLEX forte



We cannot ignore pain!
Why hurt when you can prevent it?

Product:	Orthoflex Forte®
Composition:	Hyaluronic Acid
Indication:	Osteoarthritis
Concentration:	30 mg/2ml
Treatment:	1-3 injections, OA=level 1 and 2
Molecular weight:	2,4- 2,9 MilDa
Effect:	Lubrication, growth of cartilage and bone, reducing inflammation
Packaging:	2 ml prefilled syringe in medical blister
Sterilization:	Autoclave
Shelf Life:	2 year
Storage:	Beyween +2°C and +25°C

1 injection per treatment
Intra-articular injection HYALURONIC ACID
for articular cartilage repair

What is ORTHOFLEX forte®?

ORTHOFLEX Forte® is an injectable viscose elastic solution of 30 mg/2 ml hyaluronic acid, presented in a pre-fi lled sterile syringe, which is to be administered intra articular in the treatment of osteoarthritis, leading to joint function improvement.

ORTHOFLEX Forte® is a product for viscosupplementation, which is a safe, effective and well-established treatment in osteoarthritis (OA), consisting of injecting a hyaluronic acid-based solution into the affected synovial joint.
In the joints, natural hyaluronic acid has several functions, including:

- **Lubrication**: Hyaluronic acid binds well to water, producing a viscous, jelly-like fluid. This viscous fluid provides lubrication and also acts as a cushion in the joint.

- **Growth** of cartilage and bone: Hyaluronic acid helps the growth and development of joint's cartilage and bone by promoting the growth of new cells and tissues.

- **Reducing** inflammation: Hyaluronic acid plays an important role in reducing joint inflammation and pain, caused by injury or tissue degeneration.

ORTHOFLEX FORTE®

ORTHOFLEX forte

What are the indications for treatment with ORTHOFLEX Forte®?

ORTHOFLEX Forte® is indicated in osteoarthritis, a disease of joints characterized by a progressive degradation of the cartilage and bone deformation, showing symptoms like knee pain, stiffness, articular limited mobility, crack, swelling.

ORTHOFLEX Forte® is indicated as a viscose elastic supplement or a replacement for synovial fluid in the human knee joint.

ORTHOFLEX Forte® is indicated for symptomatic treatment of knee osteoarthritis. The actions of the product are lubrication and mechanical support.



How long will the treatment take?

ORTHOFLEX Forte® is administered in the affected joint once a week, for 3 consecutive weeks. If treatment is bilateral, a separate syringe should be used for each knee.

The effect of the treatment can be maintained for 6 months. In order to prevent complications, the treatment should be repeated.

ORTHOFLEX Forte® must be administered only by medical professionals, trained for intra articular administration techniques.

Any joint effusion present should be removed by joint aspiration, before injecting **ORTHOFLEX Forte®**

What are the effects of ORTHOFLEX forte® therapy?

ORTHOFLEX Forte® have analgesic, anti-inflammatory, antioxidant and chondroprotective effects, stimulates proteoglycan, collagen and hyaluronic acid synthesis, and facilitates the evacuation of cartilaginous debris.
When the articular surfaces rub on each other, the molecules of hyaluronic acid from the synovial fluid act as a lubricant, protecting the articular surfaces from being mechanically damaged.

Under the joint loading pressure, the hyaluronic acid acts as a shock dumper, thus protecting the cartilage against compression trauma.

It feeds the cartilage and protects the synovial fluid as the hyaluronic acid represents a protective barrier for the synovial fluid.

It maintains the balance of fluids within the joint and helps the joint regain its normal function. Easy to administer, it directly treats the affected joint. Helps avoiding and preventing surgical interventions and emotional trauma.



What areas should I use this product on?
ORTHOFLEX Forte® injectable can be administered in any synovial joint of the body. These include the knee joint, hip joint, shoulder joint, and the finger joints.

ORTHOFLEX GEL®

ORTHOFLEX gel

orto brand
enjoy your life

Product:	ORTHOFLEX Gel®
Etkin Madde:	Hyaluronic Acid, Chondroitin Sulfate, N-acetil glucosamine
Indication:	Osteoarthritis, post-arthroscopy pain, following meniscus repair and previonus crossed ligament reconstruction, auxiliary treatment for osteochondral defects
Concentration:	Hyaluronic acid - 36mg/2,25ml Chondroitin sulfate - 67,5mg/2,25ml N-acetil glucosamine - 6,75mg/2,25 1
Treatment:	injection per treatment
Molecular weight:	3 MilDa
Effect:	Cartilage repair, mobility improvement, pain relief
Packaging:	2,25 ml prefilled syringe in medical blister
Sterilization:	Autoclave
Technology:	Biofermentation
Shelf Life:	2 year
Storage:	Beyween +2°C and +25°C

Intra articular injection for the treatment of osteoarthritis New innovative therapy for regeneration of articular cartilage Single injection per treatment



What is ORTHOFLEX Gel?

ORTHOFLEX Gel® is a bio-matrix in the form of a sterile, viscoelastic solution, consisting of a combination of highly purified cross-linked biopolymers: hyaluronic acid, chondroitin sulfate and n-acetylglucosamine.

ORTHOFLEX Gel® is an intra-articular injectable viscoelastic gel, used for treating osteoarthritis and it comes in a prefilled, single dose syringe.

ORTHOFLEX Gel® is very similar to the synovial fluid, a substance that occurs naturally in the joints, where it acts as a lubricant and shock absorber.

ORTHOFLEX Gel® Contains:

- Hyaluronic acid: 36 mg / 2,25 ml,
- Chondroitin sulfate: 67,5 mg / 2,25 ml
- Glucosamine 67,5 mg / 2,25 ml.

ORTHOFLEX GEL®

The high molecular weight of the gel (3,0 milDA) guarantees its excellent efficiency and a strong therapeutic effect.

HYALURONIC ACID +
CHONDROITIN SULFATE +

GLUCOSAMINE
Much more effective when used together!





How does it work?
Hyaluronic acid is a major component of the synovial fluid and cartilage and is responsible for the lubrication and cushioning in joints, providing mechanical support.

Chondroitin Sulfate is a molecule that occurs naturally in the body. It is an important component of cartilage - the tough connective tissue that cushions the joints.

Chondroitin sulfate delivers nutrients to the joint cartilage. The body needs nourishment to heal and repair itself and Chondroitin Sulfate has been proven to provide the body with the building blocks for producing new cartilage, therefore stimulating the growth of new joint cartilage.

It can also block the enzymes that degrade cartilage and inhibits pro inflammatory factors secretion.

The elasticity and plasticity, which are the functions of the joint cartilage, can be maintained through the use of Chondroitin Sulfate. Glucosamine plays a vital role in building and repairing cartilage. One of the primary physiological roles of Glucosamine is in the joints, where it stimulates the manufacture of glycosaminoglycans (GAGs) and other key structural components of cartilage. Glucosamine is now considered an essential substance for maintaining healthy joints. Studies have shown that Glucosamine and Chondroitin complement each other in inhibiting the production of inflammatory cells.

What are the indications?

ORTHOFLEX Gel® is a product for viscose supplementation, which is a safe, efficient and well established treatment in osteoarthritis. The treatment consists of injecting a hyaluronic acid and chondroitin sulfate based solution into the affected synovial joint.

ORTHOFLEX Gel® acts as a supplement and a temporary replacement for synovial fluid. It protects the cartilage and it treats the pain and the restricted mobility and elasticity that follow traumatic pathology in the knee joint and other synovial joints.

ORTHOFLEX Gel® is a solution for joint recovery after arthroscopy. By replacing the synovial fluid post-arthroscopy it will prevent post-operative complications.
It is also indicated for:

- Reducing pain after arthroscopy,
- Meniscus repair,
- Previous crossed ligament reconstruction
- As an auxiliary treatment for patients with osteochondral defects.

What is the treatment?
ORTHOFLEX Gel® must be administered strictly intra-articular, twice a year, every 6 months, according to the doctor's recommendations.

Any joint effusion present should be removed by joint aspiration, before injecting **ORTHOFLEX Gel®** . After the injection, an articular rest of approximately 24 hours is recommended (no strenuous exercise), in order to augment the duration of the effect. General rest and applying ice to the injected joint are helpful.

ORTHOFLEX TENDON®

ORTHOFLEX
tendon



Product:	Orthoflex Tendon®
Composition:	Hyaluronic Acid, Mannitol
Indication:	Tendinopathy
Concentration:	40 mg/2ml hyaluronic acid 10mg/2 ml mannitol
Treatment:	2 Injectıon at weekly ıntervals
Molecular weight:	3 MilDa
Effect:	Reduces pain, restores mobility
Packaging:	2 ml prefilled syringe in medical blister
Sterilization:	Autoclave
Technology:	Biofermentation
Raf ömrü:	2 year
Storage:	Beyween +2°C and +25°C

DISCOVER
THE NEW INNOVATIVE TREATMENT
FOR TENDINOPATHY INJECTABLE
HYALURONIC ACID + MANNITOL



DISCOVER the new innovative treatment for tendinopathy

What is ORTHOFLEX Tendon®?
ORTHOFLEX Tendon® is used for the treatment of pain and reduced mobility due to tendon disorders.

ORTHOFLEX Tendon® will be injected around the affected tendon or into the tendon sheath.

Due to its lubricating and visco-elastic properties, a single injection with **ORTHOFLEX Tendon®** provides rapid pain relief, helping restore the regenerative and restorative functions.

ORTHOFLEX Tendon® is an injectable solution, presented in a prefilled syringe.

ORTHOFLEX Tendon® consists of:
· 40mg/2ml hyaluronic acid, obtained by bio fermentation,
· 10 mg mannitol - a free radical scavenger that helps stabilize the chains of sodium hyaluronate.

What is tendinopathy?
Tendinopathy is a disease of the tendon caused by wear and tear, overuse, or incorrect use of the joints in the body.

Most tendon injuries occur near joints. The most well-known tendons are the Achilles tendon (the largest tendon in the human body, located at the heel), the biceps tendon, the hand tendons, and the elbow tendon.

ORTHOFLEX TENDON®

ORTHOFLEX tendon

Due to its macromolecular meshwork **ORTHOFLEX Tendon®** reduces the free passage of inflammatory cells and molecules and is a good transport medium for nutrients.

What are the indications?
ORTHOFLEX Tendon® is used for treating pain and restricted mobility in tendon disorders:





- Achilles tendinopathy
- Posterior tibial tendinopathy
- Peroneal tendinopathy
- **Shoulder** – rotator cuff tendinopathy
- **Elbow** – lateral and medial epicondylalgia
- **Knee** – patellar tendinopathy

How is ORTHOFLEX Tendon® administered?

ORTHOFLEX Tendon® will be injected around the affected tendon or into the tendon sheath, once a week, 2 injections in total.

Intrasheath injection - in tendon with a sheath - **ORTHOFLEX Tendon®** will be injected into the tendon sheath, in the affected area.

Peritendinous injection - in tendon without a sheath - **ORTHOFLEX Tendon®** will be injected along the affected tendon, but not in the tendon.

In both cases, **ORTHOFLEX Tendon®** will spread throughout the tendon.

Several tendons may be treated at the same time. If symptoms return, the treatment can be repeated. Ultrasound guidance is recommended during injection, to avoid nerve and blood vessels damage.

BIVIDERMA

NEW GENERATION LONG-TERM PERMANENT HA FILLER

ADVANTAGES OF BIVIDERMA

Long Term Permanence, 1-1.5 years permanence with MLC Technology)

Easy Molding (Small Particle Size, High Hydrophilic Capacity)

Strong viscosity (Stays in the applied area, does not undergo inter-tissue migration)

Safe and Removable (Easily dissolvable when needed)



Utilizing the MSC (Multi-Stage Crosslinked) patented technology, a three-layered structure is formed in the shape of microspheres, creating a Next-Generation Long-Lasting HA Filler.
It does not contain the "BDDE" agent.

BIVIDERMA

NEW GENERATION LONG-TERM PERMANENT HA FILLER



* Data on file

Result of centrifugation at 3000 rpm for 30 minutes
(500 cc of water added to a 1 cc sample)

At the conclusion of the Bividerma production process, as it does not contain any aprax binding agent, the finished product is 100% pure HYALURONIC ACID. Therefore, Bividerma boasts a significantly higher moisture retention capacity compared to all other HA fillers. Additionally, it exhibits a greater volumizing effect relative to equivalent amounts of other fillers.

Bividerma 10 ml

Sterile Absorbable Hyaluronic Acid Dermal Filler

Safe usage for long-lasting effectiveness in cases where vaginal tightening is desired.

BIVIDERMA HYALURONİDASE TEST



* Data on file

Coltrix®
COLLYGEN GCR Membrane






Guided Hyaline Cartilage Regeneration

COLTRIX® Cartiregen
Scaffold that supports Cartilage Regeneration
Type 1 Collagen (Atelocollagen) Membrane

COLTRIX ® TendoRegen
Tendon, Ligament and Connective Tissue
Strengthening Type 1 Collagen
(Atelocollagen) Membrane

Tip 1 Collagen (Atelocollagen) Membran

Coltrix, focal articular cartilage
Indicated for the treatment of defects,
highly purified acellular
Type I is the Atelocollagen
membrane.

HEMAGEN PRP KIT

The most effective and easiest way to obtain platelet rich plasma (PRP) from platelet is HEMAGEN PRP kit;

- Leader in the Turkish Market
- Easy to Use
- Compact design that can be used even in the office environment
- Minimal risk of contamination
- High Platelet concentration ratio
- Visible «BUFFY COAT»
- Adjustable PRP Concentration levels
- Short preparation tim e of 15 minutes
- Official institution registered
- Official and proven cell counts
- The only PRP kit with a clinical study in Turkey

Content of the Blood
93 % RBCs
6 % Trombositler
1 % WBCs Plazma

PRP Content
94 % Platelets and Plasma
5% WBCs

TISSUE GRAFT SOLUTIONS - PASCO2 TECHNOLOGY

AVRASYA DOKU BANKASI • ETB • EURASIA TISSUE BANK •

GREENTECH BIOTECHNOLOGY

Dental Products

Cancellous Chips

Cancellous Chips 0,5 cc	ETB2000FD
Cancellous Chips 1 cc	ETB2001FD
Cancellous Chips 1,5 cc	ETB2002FD
Cancellous Chips 2-3 cc	ETB2003FD
Cancellous Chips 5 cc	ETB2004FD
Cancellous Chips 10 cc	ETB2005FD
Cancellous Chips 15 cc	ETB2006FD
Cancellous Chips 20 cc	ETB2007FD
Cancellous Chips 30 cc	ETB2008FD
Cancellous Chips 40 cc	ETB2009FD
Cancellous Chips 50 cc	ETB2010FD
Cancellous Chips 60 cc	ETB2011FD

Cortical Chips

Cortical Chip s 0,5 cc	ETB2012FD
Cortical Chip s 1 cc	ETB2013FD
Cortical Chip s 1,5 cc	ETB2014FD
Cortical Chip s 2-3 cc	ETB2015FD
Cortical Chip s 5 cc	ETB2016FD
Cortical Chip s 10 cc	ETB2017FD
Cortical Chip s 15 cc	ETB2018FD
Cortical Chip s 20 cc	ETB2019FD
Cortical Chip s 30 cc	ETB2020FD
Cortical Chip s 40 cc	ETB2021FD
Cortical Chip s 50 cc	ETB2022FD
Cortical Chip s 60 cc	ETB2023FD

Cortical Cancellous Chips

Cortical Cancellous 0,5 cc	ETB2024FD
Cortical Cancellous 1 cc	ETB2025FD
Cortical Cancellous 1,5 cc	ETB2026FD
Cortical Cancellous 2-3 cc	ETB2027FD
Cortical Cancellous 5 cc	ETB2028FD
Cortical Cancellous 10 cc	ETB2029FD
Cortical Cancellous 15 cc	ETB2030FD
Cortical Cancellous 20 cc	ETB2031FD
Cortical Cancellous 30 cc	ETB2032FD
Cortical Cancellous 40 cc	ETB2033FD
Cortical Cancellous 50 cc	ETB2034FD
Cortical Cancellous 60 cc	ETB2035FD

Dental Products

Spongy Block

1000-3000 mm³	ETB6000FD
3001-10000 mm³	ETB6001FD
10001-25000 mm³	ETB6002FD
25001 mm³ ve üzeri	ETB6003FD

Demineralized Bone Matrix Products

Demineralized Bone Matrix Putty

DBM Putty 1 cc	ETB7000FD
DBM Putty 2 cc	ETB7001FD
DBM Putty 3 cc	ETB7002FD
DBM Putty 4cc	ETB7003FD
DBM Putty 5cc	ETB7004FD

Demineralized Bone Matrix Powder

Demineralized Bone Matrix Powder 0,5 cc	ETB7007FD
Demineralized Bone Matrix Powder 1 cc	ETB7008FD
Demineralized Bone Matrix Powder Toz 1,5 cc	ETB7009FD
Demineralized Bone Matrix Powder Toz 2 cc	ETB7010FD
Demineralized Bone Matrix Powder Toz 2,5 cc	ETB7011FD
Demineralized Bone Matrix Powder Toz 3 cc	ETB7011FD
Demineralized Bone Matrix Powder Toz 4 cc	ETB7012FD
Demineralized Bone Matrix Powder Toz 4,5 cc	ETB7013FD
Demineralized Bone Matrix Powder Toz 5 cc	ETB7014FD

TISSUE GRAFT SOLUTIONS - PASCO2 TECHNOLOGY

AVRASYA DOKU BANKASI • ETB • EURASIA TISSUE BANK •

Structural Grafts

Demineralized Bone Matrix Cube

10 mm x 10 mm x 10 mm	ETB7015FD
15 mm x 15 mm x 15 mm	ETB7016FD
20 mm x 20 mm x 20 mm	ETB7017FD

Demineralized Bone Matrix Strip

15 mm x 40 mm x 3-10 mm	ETB7018FD
15 mm x 50 mm x 3-10 mm	ETB7019FD
25 mm x 40 mm x 3-10 mm	ETB7020FD
25 mm x 50 mm x 3-10 mm	ETB7021FD

Structural Grafts

Femoral Shaft

10-15 mm	ETB3000FD
16-30 mm	ETB3001FD
31-50 mm	ETB3002FD
51-70 mm	ETB3003FD
71-100 mm	ETB3004FD
101-120 mm	ETB3005FD
121- 150 mm	ETB3006FD
151- 170 mm	ETB3007FD
171- 200 mm	ETB3008FD
201- 250 mm	ET B3009FD
251 mm and above	ETB3010FD

Fibula Shaft

5-10 mm	ETB3017FD
11-20 mm	ETB3018FD
21-30 mm	ETB3019FD
31-40 mm	ETB3020FD
41-50 mm	ETB3021FD
51-70 mm	ETB3022FD
71-100 mm	ETB3023FD
101-150 mm	ETB3024FD
151-200 mm	ETB3025FD
201-250 mm	ETB3026FD

Humeral Shaft

15-30 mm	ETB3011FD
31-50 mm	ETB3012FD
51-70 mm	ETB3013FD
71-100 mm	ETB3014FD
101-150 mm	ETB3015FD
151 mm and above	ETB3016FD

Femoral Strut

50-100 mm	ETB3027FD
50-100 mm	ETB3028FD
101-150 mm	ETB3029FD
101-150 mm	ETB3030FD
151-200 mm	ETB3031FD
151-200 mm	ETB3032FD
201 mm and above	ETB3033FD
201 mm and above	ETB3034FD

Cortical Strut

Cortical Strut Single 50-100 mm	ETB3035FD
Cortical Strut Dual 50-100 mm	ETB3036FD
Cortical Strut Single 101-150 mm	ETB3037FD
Cortical Strut Bilateral 101-150 mm	ETB3038FD
Cortical Strut Single 151-200 mm	ETB3039FD
Cortical Strut Dual 151-200 mm	ETB3040FD
Cortical Strut Single 201 mm and above	ETB3041FD
Cortical Strut Bilateral 201 mm and above	ETB3042FD

TISSUE GRAFT SOLUTIONS - PASCO2 TECHNOLOGY

Structural Grafts

Cortical Cancellous Matchstick

Single 50-100 mm	ETB3043FD
Double 50-100 mm	ETB3044FD
Single 101-150 mm	ETB3045FD
Double 101-150 mm	ETB3046FD
Single 151-200 mm	ETB3047FD
Double 151-200 mm	ETB3048FD
Single 201 mm and above	ETB3049FD
Double 201 mm and above	ETB3050FD

Tibial Shaft

20-40 mm	ETB3051FD
41-70 mm	ETB3052FD
71-100 mm	ETB3053FD
101-150 mm	ETB3054FD
151-200 mm	ETB3055FD

Radius Shaft

Radius Shaft below 50	ETB3056FD
Radius Shaft 50 mm and above	ETB3057FD

Cortical Shaft Hemi-Femoral

30-50 mm	ETB3060FD
51-100 mm	ETB3061FD
101-150 mm	ETB3062FD
151-200 mm	ETB3063FD
201-250 mm	ETB3064FD
251 mm and above	ETB3065FD

Cortical Shaft Hemi Tibial

30-50 mm	ETB3066FD
51-100 mm	ETB3067FD
101-150 mm	ETB3068FD
151-200 mm	ETB3069FD
201-250 mm	ETB3070FD
251 mm and above	ETB3071FD

Ulna Shaft

Ulna Shaft less than 50 mm	ETB3058FD
Ulna Shaft 50 mm and above	ETB3059FD

Cartilage Products

Cartilage Tissue Powder

0,5 cc	ETB9000FD
1 cc	ETB9001F
1,5 cc	ETB9002FD
2 cc	ETB9003FD
2,5 cc	ETB9004FD
3 cc	ETB9005FD
3,5 cc	ETB9006F
4 cc	ETB9007F
4,5 cc	ETB9008F
5 cc	ETB9009F

Cartilage Tissue Powder

0,5 cc	ETB9000FD
1 cc	ETB9001F
1,5 cc	ETB9002FD
2 cc	ETB9003FD
2,5 cc	ETB9004FD
3 cc	ETB9005FD
3,5 cc	ETB9006F
4 cc	ETB9007F
4,5 cc	ETB9008F
5 cc	ETB9009F

Structural Grafts

Structural Total Bones

Femoral Head Cartilage All lengths and thicknesses	ETB4000FD
Femoral Head Cartilage All lengths and thicknesses	ETB4001FD
Proximal Femur Head Left (Head-Neck-Metaphysis) All sizes and thicknesses	ETB4002FD
Proximal Femur Head Right (Head-Neck-Metaphysis) All sizes and thicknesses	ETB4003FD
Humeral Head Cartilaginous All lengths and thicknesses	ETB4004FD
Humeral Head Cartilaginous All lengths and thicknesses	ETB4005FD
Massive Ilium All sizes and thicknesses	ETB4006FD
Hemipelvis All sizes and thicknesses	ETB4007FD
Calcaneus All sizes and thicknesses	ETB4008FD
Massive Distal Humerus All sizes and thicknesses	ETB4009FD
Massive Distal Femur All sizes and thicknesses	ETB4010FD
Massive Distal Radius All sizes and thicknesses	ETB4011FD
Massive Distal Humerus All sizes and thicknesses	ETB4012FD
Massive Distal Tibia All sizes and thicknesses	ETB4013FD

Structural Total Bones

Massive Proximal Humerus All sizes and thicknesses	ETB4014FD
Massive Proximal Ulna All sizes and thicknesses	ETB4015FD
Massive Proximal Tibia All sizes and thicknesses	ETB4016FD
Massive Total Femur All lengths and thicknesses	ETB4017FD
Solid Total Tibia All sizes and thicknesses	ETB4018FD
Meniscus, Tibial Plateau All sizes and thicknesses	ETB4019FD
Without Meniscus Plate All lengths and thicknesses	ETB4020FD
Medial Left with Meniscus Plateau All sizes and thicknesses	ETB4021FF
Lateral Left with Meniscus Plateau All sizes and thicknesses	ETB4022FF
Medial Right with Meniscus Plateau All lengths and thicknesses	ETB4023FF
Lateral Right With Meniscus Plateau All lengths and thicknesses	ETB4024FF
Hemi Condyle Lateral Left All sizes and thicknesses	ETB4025FF
Hemi Condyle Lateral Left All sizes and thicknesses	ETB4026FF
Hemi Condyle Medial Right All lengths and thicknesses	ETB4027FF
Hemi Condyle Lateral Right All lengths and thicknesses	ETB4028FFV

Soft Tissue Grafts

Tendon

Tendon - Bone Conjoined, Achilles All sizes and thicknesses	ETB1000FD
Bone- Tendon-Bone Joint, Patellar All lengths and thicknesses	ETB1001FD
Achilles Tendon All sizes and thicknesses	ETB1002FD
Peroneus Longus All sizes and thicknesses	ETB1003FD
Semitendinosus All sizes and thicknesses	ETB1004FD
Tibialis Anterior All sizes and thicknesses	ETB1005FD
Tibialis Posterior All sizes and thicknesses	ETB1006FD
Gracilis Tendon All sizes and thicknesses	ETB1007FD

Fasiya Lata

1,0-2,5 cm^2	ETB5000FD
2,6-6,0 cm^2	ETB5001FD
6,1-12,0 cm^2	ETB5002FD
12,1-30,0 cm^2	ETB5003FD
30,1-60,0 cm^2	ETB5004FD
60,1-100 cm^2	ETB5005FD
100,1-150,0 cm^2	ETB5006FD
150,1-180,0 cm^2	ETB5007FD

Amniotic Membrane Products



Amniotic Membrane Disc

8 mm	ETB8000FD
10 mm	ETB8001FD
12 mm	ETB8002FD
14 mm	ETB8003FD
16 mm	ETB8004FD
20 mm	ETB8005FD
24 mm	ETB8006FD

Amniotic Membrane Patch

8 mm	ETB8000FD
10 mm	ETB8001FD
12 mm	ETB8002FD
14 mm	ETB8003FD
16 mm	ETB8004FD
20 mm	ETB8005FD
24 mm	ETB8006FD

INTRACURE NEM +

- In osteoarthritis treatment; removal of inflammation and redness,
- In the treatment of rheumatoid arthritis (inflammatory joint disease);
- It is used as a support for the protection and repair of the joint and cartilage structure, and to increase the joint mobility.
- It helps to regenerate the cartilage in pain caused by old age, obesity, sports a ctivities or after surgery, in analgesic and anti-inflammatory treatment.
- One tablet daily in the morning after a full meal.

Ingredients;

· Egg Membrane
· Dewil's Claw
· Vitamin D-3
· Vitamin K2
· Boswellia serrata

INTRACURE TYPE - 2

- It increases joint flexibility, function and strengthens joints.
- It is used as a support for treating osteoarthritis and rheumatoid arthritis problems and protecting and restructuring joint and cartilage health.
- Gluten-free.
- It supports the activation and modulation of the immune system.

Ingredients;

· Collagen Tip II
· MSM
· Mangenez
· Boswellia Serrata
· Vitamin D3
· Vitamin K2

CUREARTH COMPLEX

- In the treatment of joint diseases,
- In the nutritional support treatment in rheumatoid arthritis,
- In the treatment of osteoarthritis (Calcification),
- It plays an effective role in the treatment of cartilage-related diseases and in reducing the pain caused by this disease.
- It is recommended to be usedtwice a day after meals for adults. / 60tb

Ingredients;

· Glucosamine sulfate - 1500 mg
· Chondroitin sulfate - 600 mg
· Methyl sulfonyl methane (MSM) - 300 mg
· Boswellia serrata - 300 mg
· Type II Collagen – 40mg
· Hyaluronic Acid - 40 mg
· Turmeric Extract - 100 mg

Greentech Biotechnology

Vision:

Greentech Biotechnology's primary goal is to enhance the quality of life for individuals and support their treatments by providing supportive, specific, and specialized products for various fields and illnesses.

Mission:

Our mission is to deliver health products adhering to international standards, from production to end-users, with a conscious and sensitive approach. We aim to be a pioneering and leading company in shaping and influencing the sector.

Arthrex®

Çetin Emeç Bulvarı 41/7 06460
Çankaya / Ankara
0312 482 1 482
info@greentechbio.com.tr

GreenTech
BIOTECHNOLOGY

GreentechBiotechnology
greentechbiotec
greentechbiotechnology
Greentech Biotechnology

www.greentechbio.com.tr